Liquidia Corporation (LQDA)
Makes inhaled medicines to treat lung diseases like pulmonary hypertension.
$84.80+0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+379.6%
The outlook
Liquidia trades at $84.80 with strong analyst support (average rating: Strong Buy) and sits well above its 50- and 200-day moving averages, reflecting solid near-term momentum. The stock is near the upper end of its 52-week range, though the average analyst price target sits roughly in line with the current price. The trailing P/E of 498.8 reflects minimal or negative earnings, a factor to monitor.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 8 analysts
Price trendAbove its 50- & 200-day averages
52-week range92% of the way from its 52-week low to high
Price targetAvg target +0% vs current price
Analyst price target
~12-month · 8 analysts$84.88average target+0.1% vs now
Now $84.80
Low $60.00High $130.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$7.54B
52-wk high
$91.10
52-wk low
$16.82
50-day avg
$71.03
200-day avg
$43.69
Trailing P/E
498.8